Neoadjuvant Pepinemab in Combination with Nivolumab and/ or Ipilimumab in Resectable Stage III Melanoma

Michael C. Lowe,Brian Olson,Melinda Yushak, Crystal Mallow, Christine Reilly,Jacklyn Hammons,Brian Burns,Ali Mokhtari, Doug Parker, Terry Fisher,Elizabeth Evans, Chrystal Paulos,Keith Delman,Gregory Lesinski

ANNALS OF ONCOLOGY（2023）

引用 0|浏览5

暂无评分

摘要

SEMA4D has broad immunomodulatory effects in the tumor microenvironment; blocking SEMA4D in combination with checkpoint inhibitors (CI) promotes immune infiltration, enhances T cell activity, and promotes tumor regression. We hypothesized that the combination of pepinemab (pepi), which targets SEMA4D, and CI will increase immunomodulatory effects and augment response to neoadjuvant therapy in stage III melanoma.

查看译文

关键词

resectable stage iii melanoma,nivolumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要